Cardiac myosin activators for heart failure therapy: focus on omecamtiv mecarbil
Heart failure continues to be a major global health problem with a pronounced impact on morbidity and mortality and very limited drug treatment options especially with regard to inotropic therapy. Omecamtiv mecarbil is a first-in-class cardiac myosin activator, which increases the proportion of myos...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BioExcel Publishing Ltd
2018-04-01
|
| Series: | Drugs in Context |
| Subjects: | |
| Online Access: | http://www.drugsincontext.com/cardiac-myosin-activators-for-heart-failure-therapy-focus-on-omecamtiv-mecarbil |